Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,930.06
(
-0.09%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
90.68
(
-2.14%
)
Bitcoin
75,761.91
(
2.57%
)
News Focus
News Focus
Post# of 257431
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 247787

Wednesday, 06/28/2023 4:06:08 PM

Wednesday, June 28, 2023 4:06:08 PM

Post# of 257431
All told, it looks like LLY's Retatrutide—(and similar drugs such as Hanmi's HM15211)—will have a narrow therapeutic window, if there is any window at all.

LLY is a hot stock, and investors are acting as though it can do no wrong. Several mainstream news sources have (perhaps unintentionally) downplayed the safety issues of some of the weight-loss drugs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today